285 results on '"Siddiqui, Mustaqeem A."'
Search Results
2. Mortality trends in multiple myeloma after the introduction of novel therapies in the United States
3. Real-World Registry on the Pharmacotherapy of Multiple Myeloma and Associated Renal and Pulmonary Impairments in the Greater Gulf Region: Protocol for a Retrospective Real-World Data Study
4. Consensus-Based Expert Recommendations on the Management of Hemophilia A in the Gulf Region
5. Disease monitoring with quantitative serum IgA levels provides a more reliable response assessment in multiple myeloma patients
6. Immunotherapy in multiple myeloma
7. Evidence-Based Management of Chronic Lymphocytic Leukemia: Consensus Statements from the Gulf Region.
8. Acute seizures and status epilepticus in immune effector cell associated neurotoxicity syndrome (ICANS)
9. Clinical characteristics and treatment outcomes of newly diagnosed multiple myeloma with chromosome 1q abnormalities
10. Cytogenetic Features and Clinical Outcomes of Patients With Non-secretory Multiple Myeloma in the Era of Novel Agent Induction Therapy
11. A simple additive staging system for newly diagnosed multiple myeloma
12. Impact of time to antibiotic on hospital stay, intensive care unit admission, and mortality in febrile neutropenia
13. Deepening Responses after Upfront Autologous Stem Cell Transplantation in Patients with Newly Diagnosed Multiple Myeloma in the Era of Novel Agent Induction Therapy
14. Correction: MASS-FIX for the detection of monoclonal proteins and light chain N-glycosylation in routine clinical practice: a cross-sectional study of 6315 patients
15. Management of secondary immunodeficiency in hematological malignancies: a Delphi consensus from the Middle East.
16. Evidence-Based Management of Chronic Lymphocytic Leukemia: Consensus Statements from the Gulf Region
17. MASS-FIX for the detection of monoclonal proteins and light chain N-glycosylation in routine clinical practice: a cross-sectional study of 6315 patients
18. Correlation between urine ACR and 24-h proteinuria in a real-world cohort of systemic AL amyloidosis patients
19. Cytogenetic abnormalities in multiple myeloma: association with disease characteristics and treatment response
20. Treatment approaches and outcomes in plasmacytomas: analysis using a national dataset
21. Outpatient Practice Pattern for Recently Approved CAR-T in Patients with Lymphoma and Multiple Myeloma
22. Prognostic impact of combined NPM1+/FLT3− genotype in patients with acute myeloid leukemia with intermediate risk cytogenetics stratified by age and treatment modalities
23. Daratumumab, Carfilzomib, Pomalidomide and Elotuzumab for the Treatment of POEMS Syndrome- The Mayo Clinic Experience
24. Outpatient Practice Pattern for Recently Approved CAR-T in Patients with Lymphoma and Multiple Myeloma
25. P-164: Daratumumab, carfilzomib, pomalidomide and elotuzumab for the treatment of poems syndrome: the Mayo Clinic experience
26. P-209: Deepening responses post upfront ASCT in newly diagnosed multiple myeloma in the era of novel agent induction therapy
27. Risk Factors for Readmission in Patients With Cancer Comanaged by Hospitalists
28. The High Cost of Cancer Drugs and What We Can Do About It
29. An Uncommon Cause of Acute Encephalopathy in Multiple Myeloma
30. Multicentric Castleman disease: A single center experience of treatment with a focus on autologous stem cell transplantation
31. Implementing SAFER Responses to Misconduct and Responding to Biased Patient Requests ASAP
32. Characteristics and risk factors for thrombosis in POEMS syndrome: A retrospective evaluation of 230 patients
33. Mortality Trends in Multiple Myeloma after the Introduction of Novel Therapies in the United States
34. "Real-Life" Data of the Efficacy and Safety of Belantamab Mafodotin in Relapsed Multiple Myeloma- the Mayo Clinic Experience
35. An Analysis of Virus Amplification and Antitumor Responses in T-Cell Lymphoma Patients Treated with Voyager-V1 ( VSV-IFNβ-NIS)
36. Pilot Implementation of Remote Patient Monitoring Program for Outpatient Management of CAR-T Cell Therapy
37. The Impact of the Central Carbon Energy Metabolism Transcriptome in the Pathogenesis and Outcomes of Multiple Myeloma
38. Prognostic significance of acquired 1q22 gain in multiple myeloma
39. The Impact of Socioeconomic Risk Factors on the Survival Outcomes of Patients With Newly Diagnosed Multiple Myeloma: A Cross-analysis of a Population-based Registry and a Tertiary Care Center
40. Impact of stratifying levels of serum lactate dehydrogenase (LDH) at diagnosis on the overall survival (OS) in newly diagnosed multiple myeloma (NDMM).
41. Cost-effectiveness analysis of early vs. late autologous stem cell transplantation in multiple myeloma
42. Outpatient Practice Pattern and Clinical Outcome for Axicabtagene Ciloleucel in Patients with Aggressive Lymphoma
43. Clinical Characteristics and Outcomes of Patients With Primary Plasma Cell Leukemia in the Era of Novel Agent Therapy
44. Comparison of the current renal staging, progression and response criteria to predict renal survival in AL amyloidosis using a Mayo cohort
45. Use of beta blockers is associated with survival outcome of multiple myeloma patients treated with pomalidomide
46. A Taxonomic Review of Patient Complaints in Adult Hospital Medicine
47. Implications of MYC Rearrangements in Newly Diagnosed Multiple Myeloma
48. A Cross Sectional Evaluation of Light Chain N-Glycosylation By MASS-FIX in Plasma Cell Disorders
49. Continued Improvement in Survival of Patients with Newly Diagnosed Multiple Myeloma (MM)
50. Sequential Comparison of Conventional Serum Immunofixation (IFE) to Mass Spectrometry-Based Assessment (MASS FIX) in Patients with Multiple Myeloma (MM)
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.